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Destruction of peripheral lymphocytes and detrimental alterations in hematopoietic precursors are associated with influenza virus infection in
birds and humans. A prominent feature among H5N1 influenza-virus-infected patients with a severe or fatal outcome was found to be
lymphopenia and reactive hemophagocytosis. We show here that NS1 protein from human H5N1 influenza isolate A/HK/156/97 reduces both
systemic and pulmonary pro-inflammatory cytokines in an in vivo mouse model and protects against bone marrow lymphocyte depletion, an effect
which has been shown to be mediated by TNFα. These data suggest that the outcome of disease-associated lymphohematopoietic pathogenesis
with a pathogenic influenza A virus may depend on the balance between the virus-replication-induced generation of pro-inflammatory cytokines
which are a crucial component of the host's anti-viral defense and the ability of the NS1 protein, with or without the interaction of other virus
proteins, to counteract such cytokine-mediated adverse effects.
© 2006 Elsevier Inc. All rights reserved.Keywords: Influenza; Bone marrow; NS1Introduction
The influenza virus NS1 is a non-structural protein which is
found only in infected cells. It is an RNA-binding protein and
functions at an early stage of infection to regulate many cellular
processes such as inhibition of host mRNA polyadenylation,
inhibition of polyadenylated host mRNA nuclear export,
inhibition of mRNA splicing and prevention of dsRNA-
activated protein kinase R activation leading to the inhibition
of the interferon-mediated anti-viral response (Fortes et al.,
1994; Garcia-Sastre et al., 1998; Hatada et al., 1999; Lu et al.,
1994, 1995; Nemeroff et al., 1998; Qiu and Krug, 1994).
Studies with an influenza A virus NS1 deletion mutant show
that the ability of this mutant virus to replicate is impaired in
cells in the presence of a functional interferon pathway but
could replicate efficiently in cells defective in interferon
production. These data imply that the influenza virus NS1
deletion mutant is unable to prevent the activation of the⁎ Corresponding author. Fax: +44 1635 577901.
E-mail address: lisa.hyland@jenner.ac.uk (L. Hyland).
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doi:10.1016/j.virol.2006.02.012interferon-PKR system. The NS1 protein therefore acts as a
virulence factor and enhances viral pathogenesis by antagoniz-
ing the host interferon defense mechanism (Garcia-Sastre et al.,
1998; Bergmann et al., 2000). In vivo studies in pigs and in vitro
experiments in porcine lung epithelial cells have shown that
H5N1 viruses are more resistant to host generated anti-viral pro-
inflammatory cytokines such as IFNs and TNFα and that NS1
gene was associated with this resistance (Seo et al., 2002). NS1
has also been shown to stimulate the translation of viral mRNAs
(De La Luna et al., 1995) and modulate viral transcription and
replication (Shimizu et al., 1994; Falcon et al., 2004). Influenza
viruses induce apoptosis in many cell types both in vitro and in
vivo (Fesq et al., 1994; Hinshaw et al., 1994; Mori et al., 1995;
Morris et al., 1999; Price et al., 1997; Schultz-Cherry et al.,
1998). The mechanism of influenza-virus-induced apoptosis is
not yet clear, but the NS1, neuraminidase and PB1-F2 gene
products have all been shown to induce apoptosis in various
experimental systems (reviewed in Lowry, 2003). The NS1
protein is the only influenza gene product to date which has
been shown to be involved in both pro- and anti-apoptotic
pathways in influenza-virus-infected cells (Schultz-Cherry
et al., 2001; Zhirnov et al., 2002).
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from chickens to humans in 1997 (Claas et al., 1998; De Jong et
al., 1997). Infected patients suffered symptoms including
primary viral pneumonia, acute respiratory distress, multiple
organ dysfunction, lymphopenia and hemophagocytosis (Sub-
barao et al., 1998; To et al., 2001; Yuen et al., 1998). A fatal or
severe outcome in H5N1-infected individuals was found to be
associated with leukopenia or lymphopenia at the time of
admission to hospital, which was not the case with individuals
who had less severe disease (Yuen et al., 1998). Post-mortem
reports on two individuals showed reactive hemophagocytic
syndrome as the major pathological feature with elevated levels
of IL6, IL2R and IFNγ. These observations led to the
suggestion that H5N1 disease induces hypercytokinemia
complicated by hemophagocytic syndrome (Cheung et al.,
2002), and although other human influenza H1–H3 subtypes
also induce an increase in cytokine levels, they do not result in
reactive hemophagocytic syndrome (Hennet et al., 1992; To et
al., 2001; Van Reeth et al., 1998).
In the present study, we investigated whether the NS1
protein could influence the pathogenesis of influenza virus
infection in vivo. A novel virus was created by reverse
genetics with the NS1 gene of the human reassortant H3N2
x31 virus substituted with the NS1 gene from the H5N1/156/
1997 virus. We show here that the resulting RG-x31-156NS1
virus induced lower levels of pulmonary and systemic pro-
inflammatory cytokines and reduced bone marrow (BM)
lymphocyte depletion compared to x31. These data demon-
strate that the NS1 protein influences lymphohematopoietic
pathogenesis in vivo and may therefore influence the severity
of disease outcome.
Results
x31 and RG-x31-156NS1 replicate to a similar extent in vivo
Replication in vivo of RG-x31-156NS1 compared to x31
was assessed in lungs from infected mice at certain days post-
infection (p.i.). Both viruses replicated to a similar degree,
peaking at day 5 p.i. and were cleared by approximately day
10 p.i. (Fig. 1).Fig. 1. x31 and RG-x31-156NS1 (x31-NS) replicate to an equal extent in vivo.
Mice were infected i.n. with x31 or RG-x31-156NS1, and lungs were collected
at the indicated days p.i. for analysis of virus titers. Data represent 3 individual
mice per timepoint and are representative of two independent experiments.Pulmonary and systemic TNFα and IFNγ levels are reduced in
mice infected with RG-x31-156NS1 compared to those infected
with x31
Pro-inflammatory cytokine levels from whole homogenized
lungs and serum of mice which had been infected with RG-x31-
156NS1 and x31 were measured. Levels of lung cytokines
including TNFα and IFNγ were greatly reduced in RG-x31-
156NS1-infected mice compared to those infected with x31
particularly on day 5 p.i. (Figs. 2A–D). Although TNFα and
IFNγ levels in the serum of RG-x31-156NS1 compared to x31-
infected mice did not show such marked decreases as those
observed in the lung, we nevertheless could detect a decrease in
these cytokines in the serum on day 5 p.i. (Figs. 2E–F).
RG-x31-156NS1-infected mice are largely protected from bone
marrow lymphoid depletion
We previously showed that, during the course of an acute
infection with x31, a BM lymphoid depletion occurs which is
largely mediated by TNFα (Sedger et al., 2002). We therefore
analyzed the numbers of CD43lo/−B220lo cells (which
represent the pre-B/immature B cell population) in the BM of
RG-x31-156NS1-infected mice compared to those infected with
x31. The lymphoid depletion was significantly less severe in
mice which had been infected with RG-x31-156NS1 compared
to x31 (Fig. 3), and the peak of lymphoid depletion occurred at
approximately day 9 p.i. for both viruses. The ability of x31 to
deplete BM lymphoid cells on days 5 and 7 p.i. was found to be
dose-dependent, with a dose of 1 × 105 EID50 x31 resulting in
significantly greater BM lymphoid depletion than 1 × 103 EID50
x31. A dose-dependent loss of early B cells was not however
observed for RG-x31-156 NS1 at either timepoint (Fig. 4A
shows data obtained at day 5 p.i., and Fig. 4B shows data
obtained at day 7 p.i.). In order to determine whether the dose-
related lymphoid depletion was associated with the amount of
anti-viral TNFα and IFNγ generated, we measured the levels of
these cytokines on day 5 and day 7 p.i. in the lungs of mice
given various doses of x31 and RG-x31-156 NS1. The mice that
had been infected with x31 5 days previously showed a clear
dose-related effect in lung TNFα and IFNγ levels (Figs. 4C, D).
No dose-dependent effect in lung TNFα and IFNγ levels was
found in mice that had been infected with RG-x31-156 NS1 5
days previously. There was no difference in the lung virus titers
measured 5 days after infection with 1 × 103 EID50, 1 × 10
4
EID50 or 1 × 10
5 EID50 x31 or RG-x31-156 NS1 (Fig. 4E). The
fact that 10-fold different doses were used for infection and yet
virus titers are similar on day 5 p.i. may suggest the possibility
that the difference in levels of lung pro-inflammatory cytokines
observed from days 3 to 7 p.i. was generated early in the
response when the virus load was different.
The efficacy of the anti-viral immune response is similar in
RG-x31-156NS1 compared to x31-infected mice
As pro-inflammatory cytokine levels were found to be
reduced in the lungs of mice after infection with RG-x31-
Fig. 2. Infection of mice with RG-x31-156NS1 (x31-NS) generates lower levels of pro-inflammatory lung (A–D) and serum (E–H) cytokines compared to x31. Data
show the mean ± SD of 3 mice per group and are representative of two independent experiments. *Indicates P < 0.05.
158 L. Hyland et al. / Virology 349 (2006) 156–163156NS1, we analyzed whether the immune response to this
virus was affected by the lower levels of anti-viral cytokines
early in the immune response. We found no difference in the
numbers of CD4+ T cells, CD8+ T cells or B220+ cells in
the mediastinal lymph node on day 7 or day 9 after infection
with RG-x31-156NS1 compared to infection with x31 (Fig.
5A). Similarly, we found no difference in the numbers ofCD4+ T cells, CD8+ T cells or influenza virus tetramer
(NP)-specific (CD8+NP+) cells in the bronchoalveolar lavage
on day 7 or day 9 after infection with RG-x31-156NS1
compared to infection with x31 (Fig. 5B). Furthermore, there
was no difference in the number of IFNγ Elispots generated
in the MLN of RG-x31-156NS1 compared to x31-infected
mice on days 7 and 9 p.i. (day 7 x31: 3.37 ± 1.0 × 104;
Fig. 3. Infection with RG-x31-156NS1 (x31-NS) results in less bone marrow
lymphoid depletion compared to x31. Data show the number of CD43−
loB220lo pre-B/immature B cells in the bone marrow following infection. Each
data point shows the mean ± SD of 3–6 mice. Data are representative of three
independent experiments. *Indicates P < 0.05.
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1.28 ± 0.4 × 104) and no difference in the virus-specific
CTL response of the BAL cells on day 9 p.i. (data not
shown).
Discussion
Destruction of lymphoid tissue and peripheral leukocyte
depletion occurs in birds and mice following infection with
highly pathogenic avian influenza viruses (Tumpey et al.,
2000), and depletion of bone marrow lymphoid cells and
lymphopenia occurs following infection of mice with the
human reassortant x31 (Sedger et al., 2002). Evidence of
necrosis or apoptosis-mediated lymphocyte cell death also
occurs following infection with both avian and human viruses
(Van Campen et al., 1989; Sedger et al., 2002). In humans
infected with the pathogenic H5N1 viruses, lymphohemato-
poietic alterations occurred in most of the severely ill patients
and reactive hemophagocytic syndrome was found to be the
most prominent pathological feature (To et al., 2001).
Reactive hemophagocytic syndrome is a cytokine-driven
condition secondary to an underlying illness such as viral or
bacterial infections or a malignancy (Risdall et al., 1979;
Fisman, 2000) but has not been associated with influenza
virus infection of healthy individuals in the past. TNFα is
implicated in the pathogenesis of both hemophagocytosis and
the acute respiratory syndrome (Fisman, 2000; Headley et al.,
1997).
We show here that mice infected with RG-x31-156NS1
generate decreased levels of pulmonary and possibly systemic
TNFα and IFNγ and exhibit reduced lymphoid depletion
following infection compared to mice infected with x31. As
BM lymphoid depletion following influenza virus infection
has previously been shown to be mediated largely by TNFα
(Sedger et al., 2002), these data imply that the ability of the
NS1 protein to antagonize the production of TNFα, in
particular, results in less severe TNFα-mediated pathogenesis.
The NS1 protein from H5N1 therefore has strong cytokineantagonistic ability in vivo. NS1 sequence differences or the
amount of NS1 protein produced during infection may
therefore be important; it has previously been shown that
the presence of a glutamic acid residue at position 92 of the
NS1 protein is necessary for the resistance of H5N1/97
influenza viruses to the effects of anti-viral cytokines (Seo et
al., 2002). These data also show that NS1 is involved in
antagonizing pro-inflammatory cytokines other than IFNs in
vivo. TNFα, MCP-1 and IL6 levels were also reduced in
lung and possibly also serum of RG-x31-156NS1 compared
to x31-infected mice. The ability of NS1 to influence
production of TNFα and other pro-inflammatory cytokines
has previously been demonstrated in in vitro studies (Seo et
al., 2002; Solorzano et al., 2005; Stasakova et al., 2005). In
vivo virus-infected macrophages and epithelial cells produce
most of the pro-inflammatory cytokines following influenza
virus infection (Kaufmann et al., 2001). As the influenza-
virus-induced depletion of BM lymphoid cells is mediated
largely by TNFα and IFNs do not appear to contribute
(Sedger et al., 2002), it is likely that the NS1 protein is
indirectly influencing early BM B cells largely by antago-
nizing TNFα in this model.
The present results show that in this model immunity to
the virus is not detrimentally affected by the lower cytokine
levels generated in the mice infected with RG-x31-156NS1
compared to x31, implying that higher levels of cytokines
such as TNFα and IFNγ are not necessary to generate an
efficient immune response and may therefore only serve to
mediate pathology. No difference was found between RG-
x31-156NS1 and x31 in the numbers of antigen-specific
CD8+ T cell in the BAL, the number of IFNγ Elispots in
the MLN or the ability to mount a strong virus-specific
antibody response. However, given that similar experiments
in pigs infected with A/PR8/34 containing the NS1 gene of
H5N1 exhibited significantly greater and prolonged viremia,
fever and weight loss than those infected with wild-type A/
PR8/34 (Seo et al., 2002), it appears that disease
pathogenesis is strongly influenced by viral protein(s)
other than NS1 or by NS1 in conjunction with other viral
proteins. The results from our in vivo studies are clearly in
agreement with other in vitro studies in human and porcine
cell lines showing that the NS1 protein antagonizes pro-
inflammatory cytokines. These results however differ from
some recent works showing that the NS1 protein of H5N1/
97 viruses increases cytokine production when combined
with a A/PR8/34 (Lipatov et al., 2005) or A/WSN/33
(Cheung et al., 2002) background. These differences could
be explained by some influence or interaction of the NS1
gene with one or more genes making up this background.
While recent studies analyzing the effects of NS1 have
proposed that NS1 alone is a pathogenic factor, we suggest
that it is the interaction of NS1 with other virus protein(s)
that confers the pathogenicity associated with NS1. The fact
that the NS1 of the H5N1 virus in a A/PR8/34 background
generates higher cytokine levels than the wild-type virus but
that the NS1 in an x31 background generates lower cytokine
levels suggests that a surface protein of the background
Fig. 4. Depletion of early lymphoid CD43−/loB220lo bone marrow cells 5 days (A) and 7 days (B) p.i., and lung TNFα and IFNγ levels 5 days p.i. (C, D) are
dependent on virus dose. Mice were infected with 1 × 105, 1 × 104 or 1 × 103 EID50 x31 or RG-x31-156NS1 (x31-NS). Data represent the mean ± SD of 4–5 mice per
dose. *Indicates P < 0.05; ** indicates P < 0.01; *** indicates P < 0.001. (E) Lung virus titers 5 days p.i. 1 × 105, 1 × 104 or 1 × 103 EID50 x31 or RG-x31-156NS1
(x31-NS).
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34 and x31 viruses share the same internal genes. Perhaps
different HA or NA surface proteins confer a change in
replication kinetics or tropism of the virus. These possibil-
ities are currently being investigated.
The outcome of severe H5N1 disease may be influenced by a
range of other important factors including the immune status of
the host. It is well documented that influenza virus virulence is a
polygenic trait (Brown and Bailly, 1999; Scholtissek et al.,
1979), and the particular combination of viral genes is likely to
be crucial to pathogenesis. The ability of the NS1 protein of
influenza A virus to dampen host inflammatory responses and
thereby prevent cytokine-mediated detrimental pathologysuggests that the outcome of severe influenza disease may
reflect the degree to which pro-inflammatory cytokines are
generated. On the one hand, viral replication may generate high
levels of host anti-viral cytokines during infection, potentially
leading to cytokine-mediated pathogenesis. Alternatively, NS1-
mediated antagonism of the pro-inflammatory cytokines may
potentially interfere with the generation of host immunity,
resulting in more severe disease. Whether other highly
pathogenic strains of influenza A viruses also have NS1
proteins which are more efficient at antagonizing the cytokine-
mediated anti-viral responses and potentially less damaging to
early lymphoid cells remains to be seen. In conclusion, we
suggest that it is the interaction between the NS1 protein and
Fig. 5. The number of cells in lymphoid sub-populations in the mediastinal lymph node (A) and the bronchoalveolar lavage (B) on days 7 and 9 p.i. x31 or RG-x31-
156NS1 (x31-NS). MLN data are the mean ± SD of 5 mice per group, and BAL data are pooled from 5 mice per group.
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increases or decreases of pro-inflammatory cytokines and either
pathway can lead to pathogenesis.
Materials and methods
Mice
Wild-type C57BL/6 mice were obtained from Charles River,
UK Ltd. All mice were held under specific pathogen-free
conditions until use. Mice were used between 8 and 10 weeks of
age. All animal studies were carried out in accordance with UK
Home Office regulations and were approved by the relevant
ethics authorities.
Viruses and infection of mice
The human H5N1 virus A/HK/156/97 was obtained from the
repository of St. Jude Children's Research Hospital. Recombi-
nant influenza virus containing the NS gene from this virus and
complementary genes from the x31 laboratory strain (H3N2)
were rescued by eight-plasmid reverse genetics (Hoffmann et
al., 2000). Plasmids encoding each of the x31 genes wereconstructed as described previously (Hoffmann et al., 2002).
RNA was isolated from A/HK/156/97 and reverse transcribed
into DNA template for NS gene amplification, as previously
described (Hoffmann et al., 2001). NS PCR product was ligated
into pHW2000, and the recombinant plasmid was used to co-
transfect mixed cultures of MDCK and 293Tcells, together with
the seven complimentary x31-coding plasmids (Hoffmann et
al., 2000). Recombinant RG-x31-156NS1 virus was propagated
in 10-day-old embryonated hen eggs, and sequencing con-
firmed the appropriate NS gene in egg-grown virus. All
experiments were carried out in a Biosafety Level 3 laboratory,
and all infected animals were kept in a Biosafety Level 3
containment facility.
The HKx31 (H3N2) strain of influenza A virus (x31) was
grown in allantoic fluid (AF) of 10-day-old specific-pathogen-
free embryonated hen eggs (obtained from The Poultry
Production Unit, Institute of Animal Health, UK). x31 and
RG-x31-156NS1 grew equally well in eggs and stock titers
obtained were both 6.8 × 109 EID50/ml. Virus stocks used for
infecting mice were sterile and endotoxin-free. Mice were
anesthetized by intraperitoneal injection of ketamine/xylazine
(both from SIGMA Chemical Co., St. Louis, MO) and unless
otherwise stated were infected with 4 × 104 EID50 (50% egg
162 L. Hyland et al. / Virology 349 (2006) 156–163infectious dose) of x31 or RG-x31-156NS1 intranasally (i.n.). In
C57BL/6 mice, x31 replicates in the lungs but is cleared by 10
days p.i. For controls, mice were inoculated i.n. with an equal
volume of uninfected AF preparation. Influenza virus titers in
mouse lungs were determined by injecting 0.1 ml (and 10-fold
dilutions) of homogenized lungs into the allantoic cavity of 10-
day-old embryonated hen eggs and allowing the virus to grow
for 48–72 h at 37 °C in a humidified incubator. Presence of virus
was detected by collecting AF from each egg and testing for
hemagglutinating activity using chicken red blood cells, as
described previously (Sedger et al., 2002).
Cell preparation and flow cytometry
BAL samples were obtained post-mortem from mice by
cannulating the trachea and flushing the lungs with 4 × 1 ml of
PBS containing 0.1% BSA. The BAL cells were washed and
incubated on plastic Petri dishes for 90 min at 37 °C to remove
macrophages. BM cells were collected from femurs and tibias
of mice. BM erythrocytes were lysed with NH4Cl prior to flow
cytometry. Splenocyte and MLN suspensions were prepared by
mechanical disruption. BM leukocyte, MLN and splenocyte
suspensions from all mice were enumerated and analyzed
individually. Cells were incubated for 30 min at 4 °C in
staining buffer with the following primary or secondary
antibodies: PE-anti-CD43 mAb (S7), FITC-anti-B220 mAb
(RA3-6B2), FITC-anti-CD8α (53-6.7), PE-anti-CD4 (L3T4),
APC-B220 (RA3-6B2) (all PharMingen, San Diego, CA), PE-
NP tetramer (ASNENMETM; Beckman Coulter, San Diego,
CA). In all BM experiments, total BM leukocyte-gated
(residual erythrocytes only excluded) cells were analyzed
(20,000 events). For analysis of spleen, mediastinal lymph
node and BAL cells, only those cells within the lymphocyte
gate were analyzed. All samples were analyzed on a
FACSCalibur flow cytometer (Becton Dickinson, Mountain
View, CA), using CELLQuest software (Becton Dickinson).
Measurement of cytokines in serum and lung homogenates
Cytokines levels were assayed by Cytometric Bead Array
using the mouse inflammation kit (PharMingen).
IFNγ Elispot
Mixed cellulose-ester flat-bottom plates (Millipore, St.
Louis, MO) were coated overnight with 5 μg/ml rat anti-
mouse IFNγ antibody (clone R4-6A2, PharMingen, San Diego,
CA). Effector cells consisted of mediastinal lymph node cells
from x31- or RG-x31-156NS1-infected mice. Stimulator cells
consisted of splenocytes from naive mice, depleted of T cells by
incubation with anti-CD4, anti-CD8 and anti-Thy1.2 antibodies
(clones GK1.5, 53.6.72 and 30-H-12, respectively, obtained
from ATCC) followed by magnetic depletion using anti-rat IgG
Dynabeads (Dynal, Wirral, UK). Stimulators were either
infected with x31 or RG-x31-156NS1 (10EID50 per cell) for
3 h at 37°C or left uninfected then irradiated at 3000 rad.
Effectors were serially diluted and incubated with 5 × 105infected – or uninfected – stimulator cells per well for 24 h at
37 °C in 10% CO2. Elispots were detected using biotin-labeled
anti-mouse IFNγ antibody (clone XMG1.2, PharMingen)
followed by AP-coupled anti-biotin antibody (Vector, Peterbor-
ough, UK) and developed by incubation with 5-bromo-4-
chloro-3-indolyl phosphate substrate. No Elispots were ob-
served in wells containing uninfected stimulators.
Statistics
Where appropriate, data were analyzed using one-way
ANOVA followed by Tukey's multiple comparison test or by
unpaired Student's t test.
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